Skip to Main Content

Register here for FREE training to treat Opioid Use Disorder (OUD)

and qualify for the waiver to prescribe buprenorphine.

Buprenorphine is the first at-home therapy to treat OUD and offers great potential for expanding treatment.* Buprenorphine also has been proven to be a clinically effective therapy for OUD in populations including pregnant women. It’s an essential tool for you to be even better equipped to treat OUD in your community.

NH Healthy Families is sponsoring a FREE online training for providers to qualify for the waiver to prescribe buprenorphine. This training will be conducted by the American Society of Addiction Medicine (ASAM).** 

It includes:

  Four hours of live, interactive online training from 2:00 p.m. – 6:15 p.m. (ET)         Attend remotely by streaming the training on your device 

  Four hours of online training at your own pace

And you’ll also get for FREE:

  Continuing Medical Education Available

  A copy of the ASAM National Practice Guideline

  A reference guide and other clinical resources


The live session will be held in St. Louis, MO from 9:30 a.m. to 2:00 p.m. EST on: 

January 17, 2020 +

 


*Saloner, Brenden, Stoller, Kenneth B., Alexander, G. Caleb. “Moving Addiction Care to the Mainstream — Improving the Quality of Buprenorphine Treatment.” The New England Journal of Medicine 379.1. (2018): 4. Web. 10 Nov. 2018.

**ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

***Substance Abuse and Mental Health Services Administration. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.

Overview of Legislation:

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office-based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.